← ANALYST RATINGS · TIPRANKS
Cogent Biosciences (COGT): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy1 Hold0 Sell
Ratings of 8 analysts in the last 3 months12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $56.29, the highest $62.00, the lowest $52.00. The average is +90.7% from the last price of $29.52.
Analyst ratings 14
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $28.00 → $29.00+3.6% | Hold | −1.8% | Reiterated | 16.10.26on TipRanks 10:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $27.00 → $28.00+3.7% | Hold | −5.1% | Reiterated | 16.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $27.00 → $28.00+3.7% | Hold | −5.1% | Reiterated | 16.10.26on TipRanks 10:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $27.00 → $29.00+7.4% | Hold | −1.8% | Reiterated | 16.10.26on TipRanks 10:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $28.00 → $29.00+3.6% | Hold | −1.8% | Reiterated | 16.10.26on TipRanks 10:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $27.00 → $29.00+7.4% | Hold | −1.8% | Reiterated | 16.10.26on TipRanks 10:05 | — | |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $60.00 | Buy | +103.3% | Reiterated | 13.10.26on TipRanks Oct 14 06:10 | −5.7%next day +1.3% | ↗ |
| Unknown Analyst | Guggenheim | $52.00 | Buy | +76.2% | Reiterated | 06.10.26on TipRanks 16:05 | −0.5%next day +0.2% · 5 days −5.6% | ↗ |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $55.00 | Buy | +86.3% | Reiterated | 16.09.26on TipRanks 08:09 | −0.2%next day +0.9% · 5 days −5.6% | ↗ |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $55.00 | Buy | +86.3% | Reiterated | 16.09.26on TipRanks Sep 15 08:50 | −1.5%next day −0.2% · 5 days −2.7% | ↗ |
| Sam Slutsky★★★★★★★★★★#35 · hits 55% · avg +49.4% | LifeSci Capital | $55.00 | Buy | +86.3% | Reiterated | 15.09.26on TipRanks 13:11 | −1.5%next day −0.2% · 5 days −2.7% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $62.00 | Buy | +110.0% | Reiterated | 09.09.26on TipRanks 07:10 | −2.7%next day +0.3% · 5 days −3.7% | ↗ |
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $52.00 → $55.00+5.8% | Buy | +86.3% | Reiterated | 17.08.26on TipRanks 07:20 | +0.3%next day −0.6% · 5 days −3.1% | ↗ |
| Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% | Guggenheim | $45.00 → $52.00+15.6% | Buy | +76.2% | Reiterated | 11.08.26on TipRanks Aug 12 07:10 | −6.5%next day +0.5% · 5 days −3.0% | ↗ |
| Ami Fadia★★★★★★★★★★#73 · hits 59% · avg +36.1% | Needham | — | Hold | — | Assigned | 11.08.26on TipRanks Aug 10 18:15 | −6.5%next day +0.5% · 5 days −3.0% | ↗ |
| Laura Prendergast★★★★★★★★★★#345 · hits 76% · avg +52.4% | Stifel Nicolaus | $45.00 | Buy | +52.4% | Reiterated | 15.06.26on TipRanks 10:35 | −1.6%next day +0.3% · 5 days +12.0% | ↗ |
| Faisal Khurshid★★★★★★★★★★#51 · hits 66% · avg +74.6% | Jefferies | $55.00 | Buy | +86.3% | Initiated | 16.03.26on TipRanks 09:30 | +3.9%next day −1.0% · 5 days +1.0% | ↗ |
| Colleen M. Kusy★★★★★★★★★★#12105 · hits 35% · avg −6.9% | Robert W. Baird | $34.00 → $35.00+2.9% | Hold | +18.6% | Reiterated | 19.02.26on TipRanks 09:05 | +0.2%next day −3.3% · 5 days +2.2% | ↗ |
| Christopher Raymond★★★★★★★★★★#4074 · hits 45% · avg +2.6% | Raymond James | $60.00 | Buy | +103.3% | Reiterated | 26.01.26on TipRanks Jan 27 06:15 | +2.7%next day +1.3% · 5 days −0.1% | ↗ |
| Andrew Berens★★★★★★★★★★#336 · hits 49% · avg +24.7% | Leerink Partners | $18.00 → $50.00+177.8% | Buy | +69.4% | Assigned | 10.11.25on TipRanks 14:25 | +117.5%next day +2.7% · 5 days +6.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Cogent Biosciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $55.67 at a price of $32.02 (+73.8%); now: $56.29 at $29.52 (+90.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 9 | 8 | 3 | 4 | 6 |
| Buy | 9 | 7 | 5 | 7 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.56 (from $-0.64 to $-0.43). Last quarter: $-0.52.
Best top-analyst consensus in the sector · Healthcare
About Cogent Biosciences
- CEO: Andrew R. Robbins
- Employees: 258
- 180 Third Avenue, Waltham, MA, 02451, US
- www.cogentbio.com
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 61 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗